Login & Signup

  • PreIPO
  • Startup Fund Raising
  • Valuations
  • Equity Restructing

  • Investments
  • Mutual Funds
  • Demat Account
  • Bonds/NCD
  • Insurance
  • Life Insurance
  • Health Insurance
  • Car Insurance
  • Corporates & Business
  • Property Insurance
  • Group Health Insurance
  • Marine Insurance

RATING

RECOMMENDATION

Neutral

  • Portfolio

  • Basket

  • Watchlist

  • More

RATING

RECOMMENDATION

Neutral

Business Type

Near Leader

  • Sigachi Laboratories Unlisted Shares Essentials

Discover and get complete analysis on Sigachi Laboratories upcoming IPO unlisted shares - Management, Business Model, Financials, Growth, Valuations, Funding Rounds, News and latest updates.

ISIN

INE368H01018

Face Value

₹10.00

Total Share

67,53,100

Total Income

₹172.58 L

Profit After Tax

₹70.66 L

EPS

₹1.05

Book Value

₹2,063.00 L

Intrinsic Value

-₹3.68

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Upcoming IPO

Cashflow - Operations

-₹1.67 L

Sigachi Laboratories Growth

Compounded Sales Growth

  • -12.74%

    1 Year

  • -9.15%

    2 Year

  • -5.54%

    3 Year

Pro Only

Compounded Profit Growth

  • -32.39%

    1 Year

  • -20.25%

    2 Year

  • -15.18%

    3 Year

Pro Only

Return On Equity

  • 3.42%

    1 Year

  • 5.07%

    2 Year

  • 5.89%

    3 Year

Pro Only

About Sigachi Laboratories

  • Sigachi Laboratories Limited is a Public incorporated on 21st November 1994. It is classified as a non-govt company and is registered at Registrar of Companies, Hyderabad. 
  • Its authorized share capital is Rs. 12,00,00,000 and its paid-up capital is Rs. 67,531,000. 
  • The current market capitalization of Sigachi Laboratories stands at Rs 2,228 Lakhs. In the latest quarter, the company has reported Gross Sales of Rs. 665 Lakhs and Total Income of Rs.172 Lakhs. 
  • The company's management includes Lekha Sai Surapaneni, Lakshmana Venkata Subba Rao Patchipulusu, Tadepalli Rao Govardhana, T Adinarayana, G M Rao, K Suneetha, TR Sekhar.
  • It is involved in the Manufacture of other chemical products. The Company majorly focuses on the business of manufacturing bulk drugs and drug intermediates.

  • Sigachi Laboratories Product & Services

Chemical Testing,
EMC Testing, 
Materials Analysis 
Petroleum and Refined Products Testing 
  • Sigachi Laboratories Industry Overview

Industry Statistics

  • India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of all medicine in the UK.
  • India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with the potential to steer the industry ahead to greater heights. 
  • Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms.
  • Indian pharmaceutical sector is expected to grow to ₹7,50,00,000 lakhs, while the medical device market is expected to grow to ₹1,87,50,000 by 2025. 
  • Pharmaceuticals export from India stood at ₹1,22,25,000 lakhs in FY20. 
  • Pharmaceutical export includes bulk drugs, intermediates, drug formulations, biologicals, Ayush and herbal products, and surgical. 
  • As of November 2020, India exported pharmaceuticals worth ₹1,18,95,000 lakhs in FY21. 
  • Pharmaceutical exports from India stood at ₹ 1,22,10,000 lakhs in FY20.

Sigachi Laboratories Strengths

  • Total asset base of the company has increased with a CAGR of 3.5% from 2017 to 2020.
  • The total equity of the company has increased with a CAGR of 3.7% from 2017 to 2020.
  • The EBIT margin of the company has increased from 64.4% in FY19 to 67.6% in FY20.
  • The company is a debt-free company.

Sigachi Laboratories Shortcomings

  • The sales revenue has dropped from ₹169 lakhs in FY19 to ₹67 lakhs in 2020.
  • Return on Equity has declined to -7.6% in FY20
  • The net profit has declined by -32.4% from ₹104 lakhs in FY19 to ₹70 lakhs in FY20

Sigachi Laboratories Opportunities

  • The COVID-19 pandemic had a moderate to high impact on the global clinical laboratory services market. 
  • Increasing cases of COVID-19 patients across the globe has led to a rise in clinical chemistry services.
  • Laboratory testing and pharma demands have increased significantly and continue to grow at a staggering rate to keep pace with suspected cases of COVID-19, thus boosting the market revenue.

Sigachi Laboratories Threats

  • A laboratory-based company has little control over external threats.
  • Threats include several factors, such as new generic products that arrive in the market, new regulations, new trade barriers, changes to health insurance regulation, and even the lack of availability of qualified staff.

Sigachi Laboratories Rating

  • RECOMMENDATION

    Neutral

  • Sigachi Laboratories Detail Info

Industry Statistics

PRIVATE LIMITED

Registered In

India

Registered Date

21/11/1994

Stock Exchange Ticker

SLabs

Reg Office: SIGACHI LABORATORIES LIMITED SR.NO.530 & 534 JINNARAM MANDAL MEDAK DISTRICT BONTHAPALLY ANDHRA PRADESH INDIA-502313

Website: None